To evaluate effectiveness and tolerability of fremanezumab administered in migraine patients, who switched from a previous anti-calcitonin gene-related peptide (CGRP) pathway monoclonal antibody (mAb), as part of their routine disease management.
No takes yet. Share an insight, caveat, or question.
Straube et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: